Compare Twist Bioscience Corp (TWST) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Xpeng Inc - ADR — how do they compare? Twist Bioscience Corp trades at $88.31 (market cap $5.45B), while Xpeng Inc - ADR trades at $13.38 (market cap $12.96B). The key difference: Xpeng Inc - ADR is far larger — about 2.4× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| TWST | XPEV | |
|---|---|---|
Market Cap | $5.45B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $102.88 | $28.07 |
52-Week Low | $24.16 | $12.09 |
Enterprise Value | $5.37B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
XPeng (XPEV) trades at $13.33, down 1.52% today, with a bearish technical signal and neutral oscillators. Revenue grew to $76.72B in 2025, but net income remained negative at -$1.14B, with improving margins. Recent news highlights global expansion, including the L03 SUV launch in Munich and Robotaxi testing, while Q2 2026 deliveries of 103,295 vehicles beat expectations, signaling demand recovery.
The stock offers upside to the $17.00 analyst target but faces risks from intense EV competition and persistent losses. Investor sentiment is mixed, with 64.7% of analysts rating it Buy, yet technical trends and cash flow volatility warrant caution. Key catalysts include new model launches and international growth, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
